Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

No 'Unicorn' High-Cost/High-Volume Drugs Expected For 2017

Executive Summary

Specialty drugs, which have been a key driver of health care spending growth in years past, are not expected to have the same impact in 2017 – mostly because there's no "unicorn" high-cost, high-volume blockbusters, like the hepatitis C virus medicines Sovaldi and Harvoni, marketed by Gilead Sciences Inc., and Viekira Pak, sold by AbbVie Inc., anticipated to enter the market next year.


Related Content

Senators Fear Viral Spread Of Gilead Pricing Strategy
Express Scripts Repatha, Praluent Deals: What It Means
CVS takes aim at PCSK9s; costs could dwarf HCV meds
It's the volume, stupid


Related Companies